6 results on '"Pratt JA"'
Search Results
2. Cannabidiol inhibits synaptic transmission in rat hippocampal cultures and slices via multiple receptor pathways.
- Author
-
Ledgerwood, CJ, Greenwood, SM, Brett, RR, Pratt, JA, Bushell, TJ, Ledgerwood, C J, Greenwood, S M, Brett, R R, Pratt, J A, and Bushell, T J
- Subjects
CANNABINOIDS ,NEURAL transmission ,HIPPOCAMPUS (Brain) ,CENTRAL nervous system diseases ,LABORATORY rats ,PATCH-clamp techniques (Electrophysiology) ,CELL receptors ,HIPPOCAMPUS physiology ,IN vitro studies ,RESEARCH ,NEURONS ,CELL culture ,ANIMAL experimentation ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,HYDROCARBONS ,RATS ,COMPARATIVE studies - Abstract
Background and Purpose: Cannabidiol (CBD) has emerged as an interesting compound with therapeutic potential in several CNS disorders. However, whether it can modulate synaptic activity in the CNS remains unclear. Here, we have investigated whether CBD modulates synaptic transmission in rat hippocampal cultures and acute slices.Experimental Approach: The effect of CBD on synaptic transmission was examined in rat hippocampal cultures and acute slices using whole cell patch clamp and standard extracellular recordings respectively.Key Results: Cannabidiol decreased synaptic activity in hippocampal cultures in a concentration-dependent and Pertussis toxin-sensitive manner. The effects of CBD in culture were significantly reduced in the presence of the cannabinoid receptor (CB(1) ) inverse agonist, LY320135 but were unaffected by the 5-HT(1A) receptor antagonist, WAY100135. In hippocampal slices, CBD inhibited basal synaptic transmission, an effect that was abolished by the proposed CB(1) receptor antagonist, AM251, in addition to LY320135 and WAY100135.Conclusions and Implications: Cannabidiol reduces synaptic transmission in hippocampal in vitro preparations and we propose a role for both 5-HT(1A) and CB(1) receptors in these CBD-mediated effects. These data offer some mechanistic insights into the effects of CBD and emphasize that further investigations into the actions of CBD in the CNS are required in order to elucidate the full therapeutic potential of CBD. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
3. Modelling prefrontal cortex deficits in schizophrenia: implications for treatment.
- Author
-
Pratt JA, Winchester C, Egerton A, Cochran SM, and Morris BJ
- Subjects
- Animals, Antipsychotic Agents pharmacology, Disease Models, Animal, Excitatory Amino Acid Antagonists, Humans, Phencyclidine, Prefrontal Cortex drug effects, Psychoses, Substance-Induced drug therapy, Psychoses, Substance-Induced psychology, gamma-Aminobutyric Acid physiology, Antipsychotic Agents therapeutic use, Prefrontal Cortex pathology, Schizophrenia drug therapy, Schizophrenia pathology
- Abstract
Current treatments of schizophrenia are compromised by their inability to treat all symptoms of the disease and their side-effects. Whilst existing antipsychotic drugs are effective against positive symptoms, they have negligible efficacy against the prefrontal cortex (PFC)-associated cognitive deficits and negative symptoms. New models that reproduce core pathophysiological features of schizophrenia are more likely to have improved predictive validity in identifying new treatments. We have developed a NMDA receptor antagonist model that reproduces core PFC deficits of schizophrenia and discuss this in relation to pathophysiology and treatments. Subchronic and chronic intermittent PCP (2.6 mg/kg i.p.) was administered to rats. PFC activity was assessed by 2-deoxyglucose imaging, parvalbumin and Kv3.1 mRNA expression, and the attentional set-shifting test (ASST) of executive function. Affymetrix gene array technology was employed to examine gene expression profile patterns. PCP treatment reduced glucose utilization in the PFC (hypofrontality). This was accompanied by a reduction in markers of GABAergic interneurones (parvalbumin and Kv3.1 mRNA expression) and deficits in the extradimensional shift dimension of the ASST. Consistent with their clinical profile, the hypofrontality was not reversed by clozapine or haloperidol. Transcriptional analysis revealed patterns of change consistent with current neurobiological theories of schizophrenia. This model mirrors core neurobiological deficits of schizophrenia; hypofrontality, altered markers of GABAergic interneurone activity and deficits in executive function. As such it is likely to be a valuable translational model for understanding the neurobiological mechanisms underlying hypofrontality and for identifying and validating novel drug targets that may restore PFC deficits in schizophrenia.
- Published
- 2008
- Full Text
- View/download PDF
4. Mecamylamine but not the alpha7 receptor antagonist alpha-bungarotoxin blocks sensitization to the locomotor stimulant effects of nicotine.
- Author
-
Kempsill FE and Pratt JA
- Subjects
- Animals, Brain metabolism, Bungarotoxins metabolism, Dose-Response Relationship, Drug, Male, Rats, Rats, Sprague-Dawley, Bungarotoxins pharmacology, Mecamylamine pharmacology, Motor Activity drug effects, Nicotine pharmacology, Nicotinic Antagonists pharmacology, Receptors, Nicotinic physiology
- Abstract
The involvement of alpha7 receptors in the locomotor stimulant effects of nicotine has been examined by determining the ability of intracerebroventricular (i.c.v.) administration of the alpha7 receptor antagonist alpha-bungarotoxin (alpha-bgt) to modify sensitization to the locomotor activating effects of chronic nicotine. Intracerebroventricular administration of alpha-bgt (0.02 - 8 nmoles) produced a dose dependent increase in convulsive behaviour. At doses less than 1.0 nmole, minimal convulsive behaviour occurred but larger doses evoked convulsions in all rats which displayed a more rapid onset time as the dose increased. The binding distribution of alpha7 receptors 20 min and 3 h following an i.c.v. administration of [(125)I]-alpha-bgt (0.02 nmoles) revealed clear binding in the hippocampus, cingulate cortex and hypothalamus which was more intense after 3 h. Rats chronically treated with nicotine (0.4 mg kg(-1)) and exposed to the locomotor activity apparatus daily acquired an increase in locomotor activity relative to the control group after 3 days of treatment which reached a maximum after 7 days of treatment and was maintained for the 2 week treatment period. Pre-treatment with mecamylamine (1 mg kg(-1)) prevented the expression of the locomotor stimulant effects of nicotine but pre-treatment with i.c.v. alpha-bgt (0.02 nmoles) did not affect nicotine-induced changes in locomotor activity. The results of this study support the conclusion that nicotinic receptors of the alpha4beta2 subtype rather than the alpha7 subtype are important in mediating the expression of the locomotor stimulant effects of nicotine.
- Published
- 2000
- Full Text
- View/download PDF
5. Changes in benzodiazepine-GABA receptor coupling in an accumbens-habenula circuit after chronic diazepam treatment.
- Author
-
Brett RR and Pratt JA
- Subjects
- Animals, Anti-Anxiety Agents administration & dosage, Autoradiography, Binding, Competitive drug effects, Diazepam administration & dosage, Drug Implants, Flunitrazepam pharmacokinetics, GABA Antagonists pharmacology, GABA-A Receptor Antagonists, Injections, Intraperitoneal, Male, Maze Learning drug effects, Nucleus Accumbens drug effects, Pyridazines pharmacokinetics, Pyridazines pharmacology, Rats, Thalamus drug effects, Anti-Anxiety Agents pharmacology, Diazepam pharmacology, Nucleus Accumbens metabolism, Receptors, GABA-A metabolism, Thalamus metabolism
- Abstract
1. The effects of subacute and of chronic diazepam treatment upon binding to the GABAA receptor have been examined by use of receptor autoradiography for determining flunitrazepam (FNZP) binding, GABA enhancement of FNZP binding. SR 95531 2-(3'-carboxy-2',propyl)-3-amino-6-p-methoxyphenylpyridazinium bromide) binding and GABA binding in parallel sections from rat brain. Prior to the autoradiographic procedures, a behavioural assessment of the rats was made in the elevated plus-maze test of anxiety. 2. Rats receiving diazepam either subacutely (3 days) or chronically (28 days) by both continuous release, from previously implanted subcutaneous silastic capsules, or by daily injection (5 mg kg-1) did not display changes in FNZP or GABA binding in any of the 47 brain structures analysed. Similarly, there were no significant effects of treatment upon mean total entries or on the open:total ratio for entries in the elevated plus-maze. 3. There were reductions in the GABA enhancement of FNZP binding in the nucleus accumbens and central grey after subacute diazepam treatment. This effect persisted in the nucleus accumbens after chronic treatment. Less marked effects occurred in the lateral habenula, dorsal raphe and substantia nigra pars compacta. In the dorsal tegmental nucleus, GABA enhancement of FNZP binding was enhanced after chronic treatment and this was accompanied by reductions in SR 95531 binding. Treatment did not otherwise affect SR 95531 binding, with the exception of the dorsal raphe where binding was decreased after subacute treatment. 4. In general, the patterns of binding produced by the two different treatment routes were very similar. However, SR 95531 binding was lower in certain hippocampal fields in the i.p. treated animals compared to the rats implanted with silastic capsules. 5. It is concluded that repeated administration of diazepam evokes changes in benzodiazepine and GABA receptor coupling, and to a lesser extent changes in low affinity GABA binding, in certain interrelated brain structures of which an accumbens-habenula circuit is a central feature. These changes occur soon after the initiation of diazepam treatment, suggesting that they are unlikely to account for tolerance to the anxiolytic effects of diazepam but may trigger and/or accompany other critical neurochemical events.
- Published
- 1995
- Full Text
- View/download PDF
6. Characteristics of conditioned taste aversion produced by nicotine in rats.
- Author
-
Kumar R, Pratt JA, and Stolerman IP
- Subjects
- Amphetamine pharmacology, Animals, Ganglionic Blockers pharmacology, Male, Mecamylamine pharmacology, Rats, Avoidance Learning drug effects, Nicotine pharmacology, Taste drug effects
- Abstract
1 Nicotine produced conditioned taste aversions in rats which were directly related to the dose of nicotine and to the number of conditioning trials. 2 The tobacco alkaloid (-)-nicotine was four to five times as potent as its stereoisomer, (+)-nicotine. 3 Mecamylamine but not hexamethonium blocked the development of taste aversions produced by nicotine. 4 Mecamylamine did not block the development of taste aversions produced by apomorphine. 5 Prolonged treatment with mecamylamine prior to conditioning did not produce supersensitivity to nicotine.
- Published
- 1983
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.